Seeking Alpha

Novo Nordisk (NVO) -1.2% after discontinuing a phase-3 trial with NovoSeven, a treatment for...

Novo Nordisk (NVO) -1.2% after discontinuing a phase-3 trial with NovoSeven, a treatment for severe bleeding.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)